Overview

Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if 5-azacitidine and sorafenib can control the disease in patients with AML or MDS. The safety of this drug combination will also be studied.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Bayer
Celgene
Onyx Therapeutics, Inc.
Treatments:
Azacitidine
Niacinamide
Sorafenib